TCR2 Therapeutics (TCRR) Short Interest Ratio & Short Volume → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free TCRR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock Analysis TCR2 Therapeutics Short Interest DataCurrent Short Volume360,900 sharesPrevious Short Volume429,100 sharesChange Vs. Previous Month-15.89%Dollar Volume Sold Short$703,755.00Short Interest Ratio / Days to Cover0.6Last Record DateMay 15, 2023Outstanding Shares39,260,000 sharesFloat Size31,340,000 sharesShort Percent of Float1.15%Today's Trading Volume3,913,300 sharesAverage Trading Volume494,777 sharesToday's Volume Vs. Average791% Short Selling TCR2 Therapeutics ? Sign up to receive the latest short interest report for TCR2 Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatTCRR Short Interest Over TimeTCRR Days to Cover Over TimeTCRR Percentage of Float Shorted Over Time Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide TCR2 Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/2023360,900 shares $703,755.00 -15.9%1.2%0.6 $1.95 4/30/2023429,100 shares $757,361.50 -21.1%N/A0.7 $1.77 4/15/2023543,800 shares $848,328.00 -6.2%N/A1 $1.56 3/31/2023579,900 shares $869,850.00 +12.1%N/A1 $1.50 3/15/2023517,400 shares $770,926.00 -19.4%1.7%0.9 $1.49 2/28/2023642,000 shares $802,500.00 -28.8%2.1%1 $1.25 Get the Latest News and Ratings for TCRR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/2023901,500 shares $1.14 million -7.2%3.0%3.2 $1.27 1/31/2023971,600 shares $1.41 million -9.2%3.2%3.3 $1.45 1/15/20231,070,000 shares $1.38 million -8.6%3.5%3.5 $1.29 12/30/20221,170,000 shares $1.17 million -8.6%3.8%3.9 $1.00 12/15/20221,280,000 shares $1.24 million +5.8%4.2%4.4 $0.97 11/30/20221,210,000 shares $1.61 million -2.4%4.0%4.9 $1.33 11/15/20221,240,000 shares $1.75 million -35.1%4.0%5.6 $1.41 10/31/20221,910,000 shares $3.00 million -3.5%6.2%7.8 $1.57 10/15/20221,980,000 shares $3.21 million -8.8%6.4%8.4 $1.62 9/30/20222,170,000 shares $3.91 million No Change7.1%8.9 $1.80 9/15/20222,170,000 shares $5.27 million +0.9%7.1%6.8 $2.43 8/31/20222,150,000 shares $5.85 million +0.9%7.0%6.1 $2.72 8/15/20222,130,000 shares $7.99 million -0.9%6.9%5.3 $3.75 7/31/20222,150,000 shares $6.84 million +3.9%7.0%5 $3.18 7/15/20222,070,000 shares $6.93 million +21.1%7.0%4.4 $3.35 6/30/20221,710,000 shares $4.96 million -24.0%5.8%3.4 $2.90 6/15/20222,250,000 shares $5.72 million +4.7%7.6%4.6 $2.54 5/31/20222,150,000 shares $4.99 million -1.4%7.3%4.8 $2.32 5/15/20222,180,000 shares $5.12 million +7.9%7.4%4.3 $2.35 4/30/20222,020,000 shares $4.30 million +20.2%6.9%3.6 $2.13 4/15/20221,680,000 shares $4.13 million -3.5%5.7%2.8 $2.46 3/31/20221,740,000 shares $4.80 million +7.4%5.9%2.8 $2.76 3/15/20221,620,000 shares $3.99 million No Change5.5%2.2 $2.46 2/28/20221,620,000 shares $4.39 million +16.6%5.6%2 $2.71 2/15/20221,390,000 shares $4.24 million +25.2%4.8%1.7 $3.05 1/31/20221,110,000 shares $3.71 million -9.0%3.8%1.4 $3.34 1/15/20221,220,000 shares $4.89 million +8.0%4.2%1.6 $4.01 12/31/20211,130,000 shares $5.27 million -43.5%3.9%1.4 $4.66 12/15/20212,000,000 shares $10.10 million +38.9%6.9%2.4 $5.05 11/30/20211,440,000 shares $7.42 million +21.0%4.9%1.6 $5.15 11/15/20211,190,000 shares $8.09 million -8.5%4.1%1.4 $6.80 10/29/20211,300,000 shares $8.19 million -15.0%3.6%1.7 $6.30 10/15/20211,530,000 shares $12.38 million -14.5%4.2%2.1 $8.09 9/30/20211,790,000 shares $15.23 million -19.0%4.9%2.8 $8.51Do This Today BEFORE Biden Wins in November (Ad)Discover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).Find out how you can too in this free video. TCRR Short Interest - Frequently Asked Questions What is TCR2 Therapeutics' current short interest? Short interest is the volume of TCR2 Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 360,900 shares of TCRR short. 1.15% of TCR2 Therapeutics' shares are currently sold short. Learn More on TCR2 Therapeutics' current short interest. What is a good short interest ratio for TCR2 Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TCRR shares currently have a short interest ratio of 1.0. Learn More on TCR2 Therapeutics's short interest ratio. What is a good short interest percentage for TCR2 Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.15% of TCR2 Therapeutics' floating shares are currently sold short. Is TCR2 Therapeutics' short interest increasing or decreasing? TCR2 Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 360,900 shares, a drop of 15.9% from the previous total of 429,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is TCR2 Therapeutics' float size? TCR2 Therapeutics currently has issued a total of 39,260,000 shares. Some of TCR2 Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. TCR2 Therapeutics currently has a public float of 31,340,000 shares. How does TCR2 Therapeutics' short interest compare to its competitors? 1.15% of TCR2 Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to TCR2 Therapeutics: Aligos Therapeutics, Inc. (0.87%), AVROBIO, Inc. (0.36%), Cidara Therapeutics, Inc. (0.18%), Entera Bio Ltd. (0.31%), Genenta Science S.p.A. (0.02%), Ikena Oncology, Inc. (5.48%), Turnstone Biologics Corp. (4.76%), Elutia Inc. (0.19%), IN8bio, Inc. (1.75%), Atara Biotherapeutics, Inc. (9.51%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Enbridge Inc. ($4.29 billion), T-Mobile US, Inc. ($4.17 billion), Charter Communications, Inc. ($3.07 billion), Occidental Petroleum Co. ($2.81 billion), Moderna, Inc. ($2.37 billion), Coinbase Global, Inc. ($2.27 billion), T. Rowe Price Group, Inc. ($1.98 billion), Verisk Analytics, Inc. ($1.94 billion), Extra Space Storage Inc. ($1.88 billion), and Xylem Inc. ($1.61 billion). View all of the most shorted stocks. What does it mean to sell short TCR2 Therapeutics stock? Short selling TCRR is an investing strategy that aims to generate trading profit from TCR2 Therapeutics as its price is falling. TCRR shares are trading down $0.09 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against TCR2 Therapeutics? A short squeeze for TCR2 Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TCRR, which in turn drives the price of the stock up even further. How often is TCR2 Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TCRR, twice per month. The most recent reporting period available is May, 15 2023. More Short Interest Resources from MarketBeat Related Companies: ALGS Short Interest Data AVRO Short Interest Data CDTX Short Interest Data ENTX Short Interest Data GNTA Short Interest Data IKNA Short Interest Data TSBX Short Interest Data ELUT Short Interest Data INAB Short Interest Data ATRA Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TCRR) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity